AbbVie Inc. (ABBV) Stock Price Prediction
Price target with bull & bear cases · AI-assisted, editorially reviewed · Re-evaluated every trading day
Our AI model’s current price target for ABBV is $286.67 — 1.2% above the latest price of $283.33.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for AbbVie hinges on the continued robust performance and market penetration of its key immunology drugs, Skyrizi and Rinvoq, successfully mitigating the revenue decline from Humira biosimilar competition. Recent strategic acquisitions, such as ImmunoGen (oncology) and Cerevel Therapeutics (neuroscience), are expected to significantly diversify and strengthen its drug pipeline, driving future growth. Positive clinical trial data for pipeline assets, like the Phase 3 AFFIRM data for Skyrizi in Crohn's disease and new drugs for Parkinson's and atopic dermatitis, could expand addressable markets and accelerate revenue. Strong free cash flow generation and a commitment to shareholder returns through dividends also support a positive outlook.
Bear Case
The bear case for AbbVie centers on the potential for more significant or prolonged impact from Humira biosimilar erosion than currently anticipated. Increased competition within the immunology market could also hinder the growth trajectory of Skyrizi and Rinvoq. The company's high debt load could become a burden, especially if interest rates rise or cash flow generation underperforms expectations. Furthermore, its elevated valuation multiples make the stock vulnerable to market corrections or any negative news regarding pipeline development or regulatory approvals. Slower-than-expected integration or underperformance of recent acquisitions could also negatively impact future earnings. Legal challenges, such as the trade secret lawsuit filed against BeiGene, represent additional risks.
Model-assessed risk level: Medium
Key Catalysts to Watch
Continued strong adoption and label expansion of Skyrizi and Rinvoq, particularly after positive Phase 3 AFFIRM data for Skyrizi in Crohn's disease.
Successful integration and commercialization of drugs from recent acquisitions (ImmunoGen, Cerevel Therapeutics), including the FDA-approved tavapadon for Parkinson's disease.
Positive clinical trial readouts for pipeline assets in neuroscience, oncology, and immunology.
Strategic collaborations, such as the partnership with Iambic for AI-driven drug discovery.
Expansion into new therapeutic areas and global markets.
Potential for further dividend increases, appealing to income investors.
Technical Backdrop
RSI-14
69.2
50-Day MA
$261.62
200-Day MA
$237.69
From 52-Wk High
-0.1%
Full momentum breakdown: Is ABBV overbought or oversold?
Model Notes
AbbVie Inc. is a global biopharmaceutical company focused on developing and commercializing advanced therapies for complex and serious diseases. Spun off from Abbott Laboratories in 2013, the company boasts a diversified portfolio spanning immunology, oncology, neuroscience, aesthetics, and eye care. While facing biosimilar competition for its blockbuster drug Humira, AbbVie has successfully pivoted towards newer growth drivers like Skyrizi and Rinvoq in immunology. Strategic acquisitions, including Allergan in 2020, ImmunoGen in 2024, and Cerevel Therapeutics in 2024, have further strengthened its pipeline and expanded its therapeutic areas.
AbbVie's stock is currently in a strong uptrend, trading near its 52-week highs and above its 200-day simple moving average. Technical indicators such as the 14-day Relative Strength Index (RSI) are in the 'Buy' or 'Strong Buy' territory (around 71-75), indicating strong positive momentum, although some sources note it may be overbought in the short term. Moving averages across various periods (5-day to 200-day) consistently suggest a 'Buy' signal. The stock has shown strong performance, outperforming 78% of its industry peers in the Biotechnology sector.
Current Street Context
October 15, 2026The AI price target for AbbVie is $286.67, indicating a slight potential upside from its current price. Analyst sentiment is largely positive, with a consensus rating of "Strong Buy" or "Buy" from a majority of firms. Average 12-month price targets from analysts range from $277.18 to $286.67, with a high forecast of $320.00. A key upcoming event is the anticipated Q3 2026 earnings report around October 30. The company's deepening pipeline in neuroscience and oncology, alongside recent acquisitions, is expected to broaden long-term growth opportunities. However, competitive pressures in its aesthetics business and potential acquisition-related earnings dilution are noted considerations.
Frequently Asked Questions
What is the price target for ABBV?
How is this forecast generated?
How accurate are stock price predictions?
Will ABBV stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews ABBV’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on ABBV
AbbVie Inc. Overview
Price, chart, analysis & financials
ABBV: Overbought or Oversold?
Updated daily
ABBV: Why Is It Moving?
Updated daily
ABBV: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers